BAKUCHIOL COMPOSITIONS FOR TREATMENT OF POST INFLAMMATORY HYPERPIGMENTATION
Methods for treating excess pigmentation, including treatment of post inflammatory hyperpigmentation (PIH), are disclosed. The disclosed methods comprise administration of a composition comprising bakuchiol substantially free of furanocoumarins to a mammal. Compositions comprising bakuchiol and methods for their preparation are also disclosed.
1 - 71 . (canceled)
72 . A composition comprising bakuchiol, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier and less than 500 ppm total furanocoumarin impurities.
73 . The composition of claim 72 , wherein the composition comprises less than 100 ppm total furanocoumarin impurities.
74 . The composition of claim 72 , wherein the composition shows no tyrosinase inhibition activity relative to a kojic acid control.
75 . The composition of claim 72 , wherein the furanocoumarin impurities comprise psoralen, isopsoralen or combinations thereof.
76 . The composition of claim 72 , wherein the composition comprises 0.001% to 99.9% by total weight of bakuchiol and a pharmaceutically, dermatologically or cosmetically acceptable carrier.
77 . The composition of claim 72 , wherein the composition is administered topically, by aerosol, by suppository, intradermically, intramuscularly or intravenously.
78 . The composition of claim 72 , wherein the composition is formulated for topical administration.
79 . The composition of claim 72 , wherein the composition comprises from about 0.1% to about 2.0% by total weight of bakuchiol.
80 . The composition of claim 72 , wherein the composition comprises about 0.5% by total weight of bakuchiol.
81 . The composition of claim 72 , wherein the composition further comprises salicylic acid or a pharmaceutically acceptable salt thereof.
82 . A composition comprising synthetic bakuchiol, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier and less than 500 ppm total furanocoumarin impurities.
83 . The composition of claim 82 , wherein the composition comprises less than 100 ppm total furanocoumarin impurities.
84 . The composition of claim 82 , wherein the composition shows no tyrosinase inhibition activity relative to a kojic acid control.
85 . The composition of claim 82 , wherein the furanocoumarin impurities comprise psoralen, isopsoralen or combinations thereof.
86 . The composition of claim 82 , wherein the composition comprises 0.001% to 99.9% by total weight of bakuchiol and a pharmaceutically, dermatologically or cosmetically acceptable carrier.
87 . The composition of claim 82 , wherein the composition is administered topically, by aerosol, by suppository, intradermically, intramuscularly or intravenously.
88 . The composition of claim 82 , wherein the composition is formulated for topical administration.
89 . The composition of claim 82 , wherein the composition comprises from about 0.1% to about 2.0% by total weight of bakuchiol.
90 . The composition of claim 82 , wherein the composition comprises about 0.5% by total weight of bakuchiol.
91 . The composition of claim 82 , wherein the composition further comprises salicylic acid or a pharmaceutically acceptable salt thereof.